Professor David I Marks MB BS PhD FRACP FRCPath is Professor of Haematology and Stem Cell Transplantation. He received his medical education at the University of Melbourne and his clinical training largely at the Royal Melbourne Hospital. He then moved to London for further training in stem cell transplantation with Professor John Goldman at the Hammersmith Hospital followed by a three-year stint in Philadelphia as Assistant Professor in Haematology/Oncology. He returned to the UK in 1996 and was appointed to a consultant position in the Bristol Bone Marrow Transplantation (BMT) Unit (which he directed) and in 2007 a Chair at the University of Bristol. Professor Marks’ research focuses on clinical aspects of stem cell transplantation, ALL, CAR T cells and infection. In 1999 he worked to initiate the first national transplant trials group and chaired the BSBMT CTC for 5 years. He was Lead Clinician of the Bristol BMT Unit from 2003–9 and 2014 until 2017. He has a major interest in inotuzumab ozagamicin, authoring several publications, and he co-authored a review on T-cell ALL in adults in Blood. In 2010 he chaired the ASH ALL education session. He was Transplant Coordinator and Deputy Chair of The National Cancer Research Institute (NCRI) ALL working group, and previously President of the British Society of Blood and Marrow Transplantation (BSBMT) and received a long service award for his work for BSBMT. He was a Member of the American Society for Blood and Marrow Transplantation Practice Guidelines Committee and Vice Chair (Europe) of the Advisory Committee of the Center for International Blood and Marrow Transplant Research.  For 4 years he was appointed Medical Director of IMPACT UK, the national transplant trials group. His work as a clinical expert to 3 NICE panels have been associated with the approval of tisagenlecleucel, inotuzumab and brexucabtagene, More recently he has been continuing giving advice as a senior member of the paediatric and adult CAR T and ALL panels, as well as continuing as part of the NCRI ALL group and EWALL. Professor Marks continues to consult with and offer advice to a number of pharmaceutical companies in the areas of ALL and CAR T cells.